Novo Nordisk和Valo Health扩大伙伴关系,开发糖尿病、肥胖症和心脏病的新治疗方法。 Novo Nordisk and Valo Health expand partnership to develop new treatments for diabetes, obesity, and heart disease.

诺沃诺迪斯克(Novo Nordisk)和瓦洛(Valo Health)正在扩大伙伴关系,以开发治疗糖尿病、肥胖症和心脏病等心血管疾病的新疗法。 Novo Nordisk and Valo Health are expanding their partnership to develop new treatments for cardiometabolic diseases like diabetes, obesity, and heart disease. Valo Health将利用其AI平台确定潜在的药物候选者,Novo Nordisk将利用其药物开发和商业化专门知识。 Valo Health will use its AI platform to identify potential drug candidates, while Novo Nordisk will utilize its drug development and commercialization expertise. 这一协作旨在解决这些疾病日益加重的全球健康负担。 This collaboration aims to tackle the increasing global health burden of these diseases.